ROSELAND, N.J. - Milestone Scientific Inc. (NYSE:MLSS), a biomedical technology company specializing in computerized drug delivery instruments, has initiated direct sales of its STA Single Tooth Anesthesia System® (STA) to Meridian Endo & Perio, a dental practice in Wisconsin. This move marks a strategic shift to direct sales for the company, as announced on Tuesday.
Meridian Endo & Perio, which operates three offices specializing in endodontics, periodontics, and implant dentistry, has embraced the STA system for its ability to enhance patient comfort during dental procedures.
Dr. Lisa Teel, a periodontist and implant surgeon at the practice, praised the system for its ease of use and its effectiveness in reducing patient anxiety related to dental anesthesia. The practice has decided to implement the STA system across all its operatory rooms, and it is expected to be used for an estimated 7,500 injections annually.
Arjan Haverhals, CEO of Milestone Scientific, expressed confidence in the direct sales model's ability to provide comprehensive support and training to customers, ensuring the technology's consistent use by dental professionals. The agreement with Meridian Endo & Perio is anticipated to generate steady recurring revenue from disposable components associated with the STA system.
Milestone Scientific's proprietary DPS Dynamic Pressure Sensing technology underpins the STA system, offering a modern alternative to the traditional syringe for various dental and medical applications. The technology allows for precise control of injection flow rates and needle tip pressure, which can improve the accuracy and comfort of subcutaneous drug delivery.
This latest partnership is part of Milestone Scientific's broader strategy to commercialize its innovative injection technologies in the medical and dental markets. The company's approach includes ongoing education and collaboration with dental study clubs, potentially expanding the use of STA technology to general dentists.
The information in this article is based on a press release statement from Milestone Scientific Inc. The company's forward-looking statements reflect management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially.
Milestone Scientific is committed to ongoing innovation and the development of its diagnostic and therapeutic injection technologies for improved patient care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.